Immune tolerance limits effective immunity to epitopes targeted by universal influenza vaccines

• Published in: The Journal of immunology (1950) Vol. 204; no. 1_Supplement; pp. 245 - 245.4
• Main Authors: McGargill, Maureen Ann, Pillai, Meenu R, Labombarde, Jocelyn, Lin, Chun-Yang, Crawford, Jeremy Chase, Chang, Ti-Cheng, Keating, Rachael, Lewis, Carlessia, Guthmiller, Jenna, Li, Quan-Zhen, Wilson, Patrick C, Thomas, Paul Glyndwr
• Format: Journal Article
• Language: English
• Published: 01.05.2020
• ISSN: 0022-1767; 1550-6606
• DOI: 10.4049/jimmunol.204.Supp.245.4

Abstract A universal influenza vaccine could save millions of lives in the event of a deadly pandemic. It is not clear why antibodies specific for conserved regions of influenza viruses are so rare. One possibility is that these antibodies have a higher potential to cross-react to self-proteins, and therefore B cells that generate these antibodies are deleted through tolerance mechanisms. Therefore, we examined whether cross-reactive influenza antibodies had a higher potential to be autoreactive than antibodies specific for one subtype of influenza. We previously demonstrated that H3N2-vaccinated mice treated with a low dose of rapamycin had more cross-reactive influenza antibodies and were better protected against subsequent lethal infections of multiple subtypes. Thus, we utilized rapamycin to increase the frequency of influenza cross-reactive antibodies, and tested whether these antibodies were more reactive to self-proteins than strain-specific antibodies. We found that mice with increased levels of cross-reactive influenza antibodies also had more IgM antibodies specific for self-antigens. Importantly, the increase in autoreactive IgM antibodies correlated with increased susceptibility to disease in mouse models of multiple sclerosis, lupus, and Guillian-Barre Syndrome. Together, our results suggest that influenza cross-reactive antibodies have the potential to be autoreactive. These data have important implications for developing universal influenza vaccines designed to generate durable influenza cross-reactive antibodies.